Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Xing-Ru Zhang, Zhi-Yu Jiang, Zeng-Rui Zhang, Hui-Jun Chen, Ke Wu, Jin-Cai He & Cheng-Long Xie. (2020) The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review. Drug Design, Development and Therapy 14, pages 845-854.
Read now
Read now
Sanne Dam-Larsen, Bahman Darkahi, Arne Glad, Dagfinn Gleditsch, Lena Gustavsson, Jorma Halttunen, Karl Erik Johansson, Andreas Pischel, Ola Reiertsen, Björn Törnqvist & Hubert Zebski. (2015) Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson’s disease in the Nordic region. Scandinavian Journal of Gastroenterology 50:12, pages 1500-1507.
Read now
Read now
Kjell Fuxe, Diego Guidolin, Luigi F Agnati & Dasiel O Borroto-Escuela. (2015) Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opinion on Therapeutic Targets 19:3, pages 377-398.
Read now
Read now
Adolfo Ramirez-Zamora & Eric Molho. (2014) Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions. Expert Review of Neurotherapeutics 14:1, pages 93-103.
Read now
Read now
Brenton A Wright & Cheryl H Waters. (2013) Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease. Expert Review of Neurotherapeutics 13:6, pages 719-729.
Read now
Read now
Robert A. Hauser. (2011) Future Treatments for Parkinson's Disease: Surfing the PD Pipeline. International Journal of Neuroscience 121:sup2, pages 53-62.
Read now
Read now
H.H. Fernandez & P. Odin. (2011) Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease. Current Medical Research and Opinion 27:5, pages 907-919.
Read now
Read now
Shadab Md, Shadabul Haque, Jasjeet Kaur Sahni, Sanjula Baboota & Javed Ali. (2011) New non-oral drug delivery systems for Parkinson's disease treatment. Expert Opinion on Drug Delivery 8:3, pages 359-374.
Read now
Read now
Lauren C Seeberger & Robert A Hauser. (2009) Levodopa/carbidopa/entacapone in Parkinson’s disease. Expert Review of Neurotherapeutics 9:7, pages 929-940.
Read now
Read now
Angelo Antonini & Eduardo Tolosa. (2009) Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Review of Neurotherapeutics 9:6, pages 859-867.
Read now
Read now
Jon Stoessl. (2008) Potential therapeutic targets for Parkinson's disease. Expert Opinion on Therapeutic Targets 12:4, pages 425-436.
Read now
Read now
Dag Nyholm & Hans Lennernäs. (2008) Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opinion on Drug Metabolism & Toxicology 4:2, pages 193-203.
Read now
Read now
Articles from other publishers (50)
Valentina Leta, Lisa Klingelhoefer, Katherine Longardner, Marta Campagnolo, Hafize Çotur Levent, Federico Aureli, Vinod Metta, Roongroj Bhidayasiri, Guy Chung‐Faye, Cristian Falup‐Pecurariu, Fabrizio Stocchi, Peter Jenner, Tobias Warnecke & K. Ray Chaudhuri. (2023) Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease. European Journal of Neurology 30:5, pages 1465-1480.
Crossref
Crossref
Rajesh Pahwa, Jason Aldred, Niodita Gupta, Emi Terasawa, Viviana Garcia-Horton, David R. Steffen, Prasanna L. Kandukuri, Vivek S. Chaudhari, Yash J. Jalundhwala, Yanjun Bao, Pavnit Kukreja & Stuart H. Isaacson. (2022) Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses. Neurology and Therapy 11:2, pages 711-723.
Crossref
Crossref
Alexander D. Huters, James Stambuli, Russell C. Klix, Mark A. Matulenko, Vincent S. Chan, Justin Simanis, David R. Hill, Rajarathnam E. Reddy, Timothy B. Towne, John R. Bellettini, Brian J. Kotecki, Benoit Cardinal-David, Jianguo Ji, Eric A. Voight, Minshan Shou, Selvakumar Balaraman, Abhishek Ashok & Soma Ghosh. (2021) Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson’s Disease. The Journal of Organic Chemistry 87:4, pages 1986-1995.
Crossref
Crossref
Christine M. Madla, Francesca K. H. Gavins, Sarah J. Trenfield & Abdul W. Basit. 2022. Biopharmaceutics. Biopharmaceutics
205
237
.
Trang N. N. Vo, Karen Frei & Daniel D. Truong. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2993
3013
.
Carlos G. Moreira, Marta M. Morawska, Aron Baumann, Sophie Masneuf, Michael Linnebank, Michael Sommerauer, Hans-Peter Landolt, Daniela Noain & Christian R. Baumann. (2020) Improved functional and histochemical outcomes in l-DOPA plus tolcapone treated VMAT2-deficient mice. Neuropharmacology 181, pages 108353.
Crossref
Crossref
Trang N. N. Vo, Karen Frei & Daniel D. Truong. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
21
.
Thomas Müller & Hans Michael Thiede. (2019) Bound, free, and total l-dopa measurement in plasma of Parkinson’s disease patients. Journal of Neural Transmission 126:11, pages 1417-1420.
Crossref
Crossref
Grace B. Hatton, Christine M. Madla, Sarit C. Rabbie & Abdul W. Basit. (2019) Gut reaction: impact of systemic diseases on gastrointestinal physiology and drug absorption. Drug Discovery Today 24:2, pages 417-427.
Crossref
Crossref
Maria Jose Catalan, Jose Antonio Molina-Arjona, Pablo Mir, Esther Cubo, Jose Matias Arbelo & Pablo Martinez-Martin. (2018) Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s disease. Journal of Neurology 265:6, pages 1279-1287.
Crossref
Crossref
Thomas Marshall, Amy Pugh, Angelyn Fairchild & Steven Hass. (2017) Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease. Value in Health 20:10, pages 1383-1393.
Crossref
Crossref
Maria José Catalán, Angelo Antonini, Matilde Calopa, Ovidiu Băjenaru, Oriol de Fábregues, Adolfo Mínguez-Castellanos, Per Odin, José Manuel García-Moreno, Stephen W. Pedersen, Zvezdan Pirtošek & Jaime Kulisevsky. (2017) Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. eNeurologicalSci 8, pages 44-53.
Crossref
Crossref
L.P. Kotra & J. Park. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
439
473
.
Dasiel O. Borroto-Escuela, Manuel Narváez, Gemma Navarro, Rafael Franco & Kjell Fuxe. 2017. G-Protein-Coupled Receptor Dimers. G-Protein-Coupled Receptor Dimers
477
501
.
Anna De Rosa, Alessandro Tessitore, Leonilda Bilo, Silvio Peluso & Giuseppe De Michele. (2016) Infusion treatments and deep brain stimulation in Parkinson's Disease: The role of nursing. Geriatric Nursing 37:6, pages 434-439.
Crossref
Crossref
Yasaman Kianirad & Tanya Simuni. (2016) Novel Approaches to Optimization of Levodopa Therapy for Parkinson’s Disease. Current Neurology and Neuroscience Reports 16:4.
Crossref
Crossref
M. Angela Cenci-Nilsson & Per Odin. 2016. Parkinson's Disease. Parkinson's Disease
63
75
.
. 2016. Parkinson's Disease. Parkinson's Disease
1
92
.
T. van Laar, D. Nyholm & R. Nyman. (2016) Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease. Acta Neurologica Scandinavica 133:3, pages 208-215.
Crossref
Crossref
Oluwadamilola O Ojo & Hubert H Fernandez. (2015) Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease. Future Neurology 10:3, pages 191-201.
Crossref
Crossref
J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra & R. Yañez. (2013) Advanced Parkinson's disease: Clinical characteristics and treatment. Part II. Neurología (English Edition) 28:9, pages 558-583.
Crossref
Crossref
J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra & R. Yañez. (2013) Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II. Neurología 28:9, pages 558-583.
Crossref
Crossref
A. Antonini, P. Odin, L. opiano, V. Tomantschger, C. Pacchetti, B. Pickut, U. E. Gasser, D. Calandrella, F. Mancini, M. Zibetti, B. Minafra, I. Bertaina, P. De Deyn, C. Cras, E. Wolf, S. Spielberger & W. Poewe. (2013) Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care. Journal of Neural Transmission 120:11, pages 1553-1558.
Crossref
Crossref
Mildred D. Gottwald & Michael J. Aminoff. 2013. Emerging Drugs and Targets for Parkinson’s Disease. Emerging Drugs and Targets for Parkinson’s Disease
110
125
.
Paul F Worth. (2013) When the going gets tough: how to select patients with Parkinson's disease for advanced therapies. Practical Neurology 13:3, pages 140-152.
Crossref
Crossref
Thomas Müller. (2013) Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease. Clinical Neuropharmacology 36:3, pages 84-91.
Crossref
Crossref
Hubert H. Fernandez, Arvydas Vanagunas, Per Odin, Alberto J. Espay, Robert A. Hauser, David G. Standaert, Krai Chatamra, Janet Benesh, Yili Pritchett, Steven L. Hass & Robert A. Lenz. (2013) Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism & Related Disorders 19:3, pages 339-345.
Crossref
Crossref
David Salat & Eduardo Tolosa. 2013. Handbook of Parkinson’s Disease. Handbook of Parkinson’s Disease
389
413
.
D. Nyholm, A. Johansson, H. Lennernäs & H. Askmark. (2011) Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. European Journal of Neurology 19:6, pages 820-826.
Crossref
Crossref
Dag Nyholm, Anders Johansson, Sten-Magnus Aquilonius, Elisabeth Hellquist, Hans Lennernäs & Håkan Askmark. (2012) Complexity of Motor Response to Different Doses of Duodenal Levodopa Infusion in Parkinson Disease. Clinical Neuropharmacology 35:1, pages 6-14.
Crossref
Crossref
Jonathan Brotchie & Peter Jenner. 2011. Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia. Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia
123
150
.
Angelo Antonini, Giulia Ursino, Daniela Calandrella, Laura Bernardi & Mauro Plebani. (2010) Continuous dopaminergic delivery in Parkinson’s disease. Journal of Neurology 257:S2, pages 305-308.
Crossref
Crossref
Alessandro StefaniMariangela PierantozziGiacomo KochSalvatore GalatiPaolo Stanzione. (2010) Therapy for dyskinesias in Parkinson’s disease patients. Future Neurology 5:2, pages 277-299.
Crossref
Crossref
Angelo Antonini, K. Ray Chaudhuri, Pablo Martinez-Martin & Per Odin. (2010) Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinsonʼs Disease. CNS Drugs 24:2, pages 119-129.
Crossref
Crossref
Susan Fox & Anthony E. Lang. 2010. MOVEMENT DISORDERS 4. MOVEMENT DISORDERS 4
252
272
.
Seppo Kaakkola. 2010. Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors. Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors
207
225
.
Erkki Nissinen. 2010. Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors. Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors
1
5
.
Soichi Itoh & Charles Oo. (2010) A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats. Journal of Pharmaceutical Sciences 99:1, pages 227-233.
Crossref
Crossref
Angelo Antonini & Per Odin. (2009) Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism & Related Disorders 15, pages S97-S100.
Crossref
Crossref
A. H. V. Schapira, M. Emre, P. Jenner & W. Poewe. (2009) Levodopa in the treatment of Parkinson’s disease. European Journal of Neurology 16:9, pages 982-989.
Crossref
Crossref
D. Nyholm, R. Constantinescu, B. Holmberg, N. Dizdar & H. Askmark. (2009) Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations. Acta Neurologica Scandinavica 119:5, pages 345-348.
Crossref
Crossref
Angelo Antonini. (2009) Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease. Journal of Movement Disorders 2:1, pages 4-9.
Crossref
Crossref
Rickard Nyman, Dan Lundgren & Dag Nyholm. (2009) Soft Tissue-anchored Transcutaneous Port Attached to an Intestinal Tube for Long-term Gastroduodenal Infusion of Levodopa/Carbidopa in Parkinson Disease. Journal of Vascular and Interventional Radiology 20:4, pages 500-505.
Crossref
Crossref
F. Raudino, P. Garavaglia, C. Pianezzola, G. Riboldazzi, S. Leva, M. Guidotti & G. Bono. (2009) Long-term experience with continuous duodenal levodopa–carbidopa infusion (Duodopa): report of six patients. Neurological Sciences 30:1, pages 85-86.
Crossref
Crossref
Ludy Shih & Daniel Tarsy. 2009. Pharmacology and Therapeutics. Pharmacology and Therapeutics
651
662
.
D. Isacson, K. Bingefors, I. S. Kristiansen & D. Nyholm. (2008) Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurologica Scandinavica 118:6, pages 379-386.
Crossref
Crossref
Jens Volkmann. (2014)
Deep Brain Stimulation or Duodenal Levodopa/Carbidopa Infusion:
Choosing the Right Therapy for Individual Patients
. CNS Spectrums 13:S7, pages 8-10.
Crossref
Crossref
Dag Nyholm, Tommy Lewander, Anders Johansson, Peter A. LeWitt, Christofer Lundqvist & Sten-Magnus Aquilonius. (2008) Enteral Levodopa/Carbidopa Infusion in Advanced Parkinson Disease. Clinical Neuropharmacology 31:2, pages 63-73.
Crossref
Crossref
Theresa A. Zesiewicz, Kelly L. Sullivan & Robert A. Hauser. (2007) Levodopa-induced Dyskinesia in Parkinson’s disease: Epidemiology, etiology, and treatment. Current Neurology and Neuroscience Reports 7:4, pages 302-310.
Crossref
Crossref
Angelo Antonini, Ioannis U. Isaias, Margherita Canesi, Maurizio Zibetti, Francesca Mancini, Luigi Manfredi, Marco Dal Fante, Leonardo Lopiano & Gianni Pezzoli. (2007) Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Movement Disorders 22:8, pages 1145-1149.
Crossref
Crossref